January 15, 2020 / 7:05 AM / 3 days ago

BRIEF-ISR Initiates Collaboration With Chinese InnoStar For The Treatment Of Hepatitis B

Jan 15 (Reuters) - ISR Immune System Regulation Holding AB :

* CO’S BOARD OF DIRECTORS DECIDED ON TUESDAY TO INITIATE STRATEGIC COLLABORATION WITH RENOWNED CHINESE CRO COMPANY SHANGHAI INNOSTAR BIOTECH

* THE GOAL OF THE COLLABORATION IS TO DEVELOP ISR’S DRUG CANDIDATE ISR050 FOR TREATMENT OF HEPATITIS B

* CO’S DRUG CANDIDATE IS NOW IN FINAL STAGE OF THE PRECLINICAL PHASE

Source text for Eikon:

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below